Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Novartis returns to the discount aisle, buys Xoma’s failed PhIII drug for $31M
Novartis returns to the discount aisle, buys Xoma’s failed PhIII drug for $31M
Novartis returns to the discount aisle, buys Xoma’s failed PhIII drug for $31M
Submitted by
admin
on August 25, 2017 - 9:53am
Source:
Endpoints
News Tags:
Novartis
Xoma
M&A
gevokizumab
cardiovascular disease
Headline:
Novartis returns to the discount aisle, buys Xoma’s failed PhIII drug for $31M
Do Not Allow Advertisers to Use My Personal information
